On Invalid Date, Beam Therapeutics (NASDAQ: BEAM) reported Q4 2023 earnings per share (EPS) of $1.91, up 453.7% year over year. Total Beam Therapeutics earnings for the quarter were $142.80 million. In the same quarter last year, Beam Therapeutics's earnings per share (EPS) was -$0.54.
As of Q1 2024, Beam Therapeutics's earnings has grown year over year. Beam Therapeutics's earnings in the past year totalled -$132.53 million.
What is BEAM's earnings date?
Beam Therapeutics's earnings date is Invalid Date. Add BEAM to your watchlist to be reminded of BEAM's next earnings announcement.
What was BEAM's revenue last quarter?
On Invalid Date, Beam Therapeutics (NASDAQ: BEAM) reported Q4 2023 revenue of $316.19 million up 1,478.04% year over year. In the same quarter last year, Beam Therapeutics's revenue was $20.04 million.
What was BEAM's revenue growth in the past year?
As of Q1 2024, Beam Therapeutics's revenue has grown 520.01% year over year. This is 354.4 percentage points higher than the US Biotechnology industry revenue growth rate of 165.61%. Beam Therapeutics's revenue in the past year totalled $377.71 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.